Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Abraxane®, Carboplatin and Bevacizumab in "Triple Negative" (Demonstrating No Expression for Estrogen, Progesterone, or Her2 Receptors) Metastatic Breast Cancer

NCT00479674 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT00479674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00479674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Abraxane®, Carboplatin and Bevacizumab in "Triple Negative" (Demonstrating No Expression for Estrogen, Progesterone, or Her2 Receptors) Metastatic Breast Cancer
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
March 31, 2014
Enrollment
41 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer